RxDoctor Payments Data

Matthew Jones, OD

Optometrist · Effingham, ILNPI 1578727368

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (45.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Alcon at 30.0% of the total. Reporting peaked in 2023 at $3,120 and has fallen 73.7% since, to $820 in 2025. Among optometrist clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,558in general payments, 2019–2025

Across 176 payments — averaging $59.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • Coopervision Inc.$3K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson Vision Care, Inc.$402
  • AbbVie$353
  • Optos, Inc.$317
  • plus $1K from 14 others

What the payments were for

  • Speaking & faculty fees$4,77045%
  • Travel & lodging$1,75717%
  • Food & beverage$3,71335%
  • Entertainment$3173%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,558 in reported general payments places this provider in the 95th percentile of 2,257 optometrist providers in Illinois.

See all optometrist providers in Illinois

Medicare billing

Part B allowed, 2024
$130,522
Medicare patients
414
Services billed
2,614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine39$34,109
Brimonidine Tartrate16$1,357
Latanoprost108$1,300
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat43$524
Prednisolone Acetate15$459
Dorzolamide Hcl18$369
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha19$153
Timolol Maleate18$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis$353$34,10939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,257 optometrist providers in Illinois.

Other optometrist in Effingham

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →